Originally published on AI Tech Connect.
What you need to know $400M Series C was announced on 14 July 2026 at a $3.8B valuation — roughly triple where the company sat about seven months earlier. Index Ventures led, alongside Kleiner Perkins, Sequoia Capital and Dimension — a blue-chip syndicate that signals conviction, not tourism. The product is pre-clinical: AI models that predict and reprogramme how molecules interact, with the Chai-1 and Chai-2 lineage already used by Eli Lilly, Novartis and Pfizer. This is a lane, not a headline: techbio is a distinct, high-value career path for AI builders — one that rewards a different skill set from LLM app work. If you have spent the past two years shipping retrieval pipelines, agent loops and chat interfaces, the Chai Discovery raise should read as a signpost rather than just another…
Top comments (0)